The Moment Your GenAI Strategy Gets Tested
There is a conversation happening in some firms right now that most would prefer to avoid.
A major client has sent revised outside counsel guidelines. The relationship partner needs to respond to questions about how the firm's AI investments translate into value for the client. They ask internally for a clear answer. What comes back is three different answers from three different people — all reasonable, none consistent.
That is not a communication problem. It is a sequencing problem that has become visible at the worst possible moment.
What the Pressure Scenario Actually Looks Like
The market shift isn't hypothetical (Thomson Reuters report). Client spend anticipation has dropped to its lowest point since the pandemic. Procurement involvement in outside counsel decisions is increasing. GCs are under pressure to demonstrate that external legal spend is producing strategic value.
For most law firms, this doesn't arrive as a single crisis. It arrives as a series of small, uncomfortable moments:
A client asks a question in a pitch that the partner can't answer cleanly. A budget review surfaces that utilization on major AI platforms is lower than the investment implied. A practice group leader pushes back on firm-wide governance requirements because they slow down a workflow that's already working. Another practice group requests a significant investment, arguing it will drive growth — and the opportunity stalls in indecision because there is no shared framework to evaluate it. A lateral candidate asks about the firm's AI capabilities and gets a different answer than the one on the website.
None of these is catastrophic individually. Together, they signal that the implicit GenAI strategy is under strain.
What Actually Breaks
Most of this sequencing happened under real urgency and incomplete information. The issue isn’t that decisions were wrong — it’s that the cumulative pattern was never examined as a whole.
When sequencing has never been made explicit, pressure doesn't produce a clean strategic debate. It produces something messier.
Governance leaders argue that expansion moved too fast and controls weren't embedded before scale. Finance questions whether utilization rates justify the license costs and wants to see ROI evidence that was never systematically collected. Practice group leaders defend their local adoption decisions — correctly — but those decisions now look inconsistent at the firm level. The managing partner, COO, and CIO are fielding questions from multiple directions without a shared narrative to anchor the response.
The investments weren't necessarily wrong. The tools may be genuinely useful. But without explicit strategic sequencing, there is no agreed answer to the question that matters most under pressure: why did we make these choices in this order, and what were we willing to trade off?
That absence is what becomes expensive — not the investment itself.
What Holds
Firms that have made their strategy sequencing explicit don't avoid pressure. But they respond to it differently, because they have a defensible answer ready.
If Trust has been leading deliberately: "We invested first in governance and risk infrastructure. We expanded capability once control standards were embedded. That's why we can speak to client confidentiality and offer quality assurance with specificity."
If Discipline has been leading: "We scaled in phases tied to measurable utilization. We know exactly where efficiency gains are real and where they aren't yet. That's the basis for the conversation we're having with you about fees."
If Positioning has been leading: "We made an early investment in capability to stay competitive for the work our clients bring us. We're now tightening measurement to sustain it. Here's what that means for how we staff your matters."
Each of these is arguable. Each involves trade-offs. But each reflects a deliberate order — and that deliberateness is what makes the response credible rather than improvised.
Clients are not necessarily looking for the cheapest firm or the firm with the most sophisticated AI tools. They are looking for the firm that can explain clearly what it's doing and why it matters for their specific situation. That explanation requires a shared internal story before it can become a coherent external one.
The Real Competitive Advantage
Competitive advantage in professional services rarely comes from early adoption alone. It comes from being able to sustain margin and client trust under constraint. Strategic sequencing affects cost-to-serve, pricing credibility, and client confidence. When those elements align, AI investment strengthens economics. When they don’t, it becomes overhead.
Most of the conversation about GenAI competitive advantage focuses on capability — which tools, which use cases, which efficiency gains. That matters. But it's increasingly table stakes.
What is harder to replicate — and what differentiates firms when conditions tighten — is the ability to make decisions quickly and consistently when the answer isn't obvious.
Should we expand this platform to two more practice groups, given the current utilization? Should we adjust our fee structure for AI-assisted work on this client's matters? Should we respond to this OCG by committing to specific efficiency metrics?
These are not technology questions. They are strategy sequencing questions.
Firms with explicit sequencing can answer those questions in a single meeting because the trade-offs were acknowledged in advance. Firms that haven’t will find themselves reopening the same debate each time — about governance, ROI, positioning, risk tolerance. The decision slows. The client waits. The internal friction compounds.
That difference is subtle in growth conditions.
It becomes decisive when pressure arrives.
Closing the Series
This series started with a simple observation: most firms aren't operating without a GenAI strategy. They're operating with three of them simultaneously, without having chosen among them.
The argument across these four pieces has been equally simple: that implicit sequencing produces friction, inconsistency, and vulnerability to exactly the kind of market pressure that is already building. And that making sequencing explicit — even imperfectly, even temporarily — is what converts AI investment from accumulation into direction.
Not because one strategy is correct. Trust First, Discipline First, and Positioning First can all work. What doesn't work, for long, is a firm full of capable people pulling in different directions without knowing it — and discovering that fact when a client is asking a question that deserves a straight answer.
A practical starting point is simple, but rarely done honestly: create a one-page inventory of every GenAI-related initiative over the past 24 months — licenses, pilots, vendor evaluations, governance projects, training, infrastructure upgrades — and estimate both the direct costs and the internal time spent. Include what you’ve told the market (website, pitches, recruiting) alongside what’s actually happening internally. It’s rarely pretty, but it makes sequencing visible fast.
There are pilots that went nowhere, tools that overlap, and investments made under pressure. In many firms, the hours spent in meetings, pilots, and rework rival — or exceed — license costs. And external communication rarely aligns with what is happening internally – which is totally okay as long as it was deliberate. That is why this inventory often clarifies sequencing faster than any abstract strategy conversation.
The firms that will look back on this period without regret will not necessarily be the ones that spent the most or adopted the fastest. They’re the ones that knew what they were optimizing for — and could explain it clearly when it mattered most.
The fifth and final blog of this series provides tips on how to start the conversation and sequence your GenAI Strategy.